Drug Profile
IMC EB10
Alternative Names: anti-FLT3 Mab-gelonin; EB10-Gelonin; IMC-EB10; IMC-EB10-geloninLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator ImClone Systems
- Developer ImClone Systems; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 24 Jan 2011 Discontinued - Phase-I for Acute myeloid leukaemia in USA (IV)
- 20 Dec 2010 ImClone completes enrolment in its phase I trial [NCT00887926] for Acute myeloid leukaemia in US
- 05 Jun 2009 Phase-I clinical trials in Acute myeloid leukaemia in USA (IV)